These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 848647)

  • 21. Endothelial cells produce a substance that inhibits contact activation of coagulation by blocking the activation of Hageman factor.
    Kleniewski J; Donaldson VH
    Proc Natl Acad Sci U S A; 1993 Jan; 90(1):198-202. PubMed ID: 8419923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator.
    Forbes CD; Pensky J; Ratnoff OD
    J Lab Clin Med; 1970 Nov; 76(5):809-15. PubMed ID: 5477337
    [No Abstract]   [Full Text] [Related]  

  • 23. New agents for thromboprotection. A role for factor XII and XIIa inhibition.
    Labberton L; Kenne E; Renné T
    Hamostaseologie; 2015; 35(4):338-50. PubMed ID: 25609114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor.
    Griffin JH; Cochrane CG
    Proc Natl Acad Sci U S A; 1976 Aug; 73(8):2554-8. PubMed ID: 1066663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases.
    Nickel KF; Long AT; Fuchs TA; Butler LM; Renné T
    Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):13-20. PubMed ID: 27834692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The so-called "contact" system of plasma: consequences of the activation of the Hageman factor].
    Damas J; Adam A
    Ann Biol Clin (Paris); 1988; 46(3):185-9. PubMed ID: 3044204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma inhibitors of the Hageman factor dependent pathways.
    Schreiber AD
    Semin Thromb Hemost; 1976 Jul; 3(1):32-51. PubMed ID: 799348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol).
    Laurel MT; Ratnoff OD; Everson B
    J Lab Clin Med; 1992 May; 119(5):580-5. PubMed ID: 1374787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.
    Schreiber AD; Kaplan AP; Austen KF
    J Clin Invest; 1973 Jun; 52(6):1402-9. PubMed ID: 4703226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. THE INDUCTION OF PERMEABILITY-INCREASING ACTIVITY IN HUMAN PLASMA BY ACTIVATED HAGEMAN FACTOR.
    RATNOFF OD; MILES AA
    Br J Exp Pathol; 1964 Jun; 45(3):328-45. PubMed ID: 14173175
    [No Abstract]   [Full Text] [Related]  

  • 31. [Contact phase of blood coagulation].
    Popova LG
    Usp Fiziol Nauk; 1980; 11(1):47-72. PubMed ID: 6989129
    [No Abstract]   [Full Text] [Related]  

  • 32. Anticoagulant activities of heparin and fragments.
    Barrowcliffe TW; Thomas DP
    Ann N Y Acad Sci; 1989; 556():132-45. PubMed ID: 2660683
    [No Abstract]   [Full Text] [Related]  

  • 33. Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.
    Ratnoff OD; Saito H
    Proc Natl Acad Sci U S A; 1979 Feb; 76(2):958-61. PubMed ID: 284420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor XI and contact activation as targets for antithrombotic therapy.
    Gailani D; Bane CE; Gruber A
    J Thromb Haemost; 2015 Aug; 13(8):1383-95. PubMed ID: 25976012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays.
    Nuijens JH; Huijbregts CC; Cohen M; Navis GO; de Vries A; Eerenberg AJ; Bakker JC; Hack CE
    Thromb Haemost; 1987 Aug; 58(2):778-85. PubMed ID: 2445044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid loss of factor XII and XI activity in ellagic acid-activated normal plasma: role of plasma inhibitors and implications for automated activated partial thromboplastin time recording.
    Joist JH; Cowan JF; Khan M
    J Lab Clin Med; 1977 Dec; 90(6):1054-65. PubMed ID: 303667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanism of an increase in the hemostatic properties of the blood under the influence of adrenaline (experimental in vitro studies)].
    Popova LG; Nikiforova LM
    Probl Gematol Pereliv Krovi; 1974; 19(5):46-8. PubMed ID: 4830589
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of Factor XII in hemostasis and thrombosis: clinical implications.
    Renné T; Gailani D
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):733-41. PubMed ID: 17605651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [LIVER AND BLOOD COAGULATION. I. BEHAVIOR OF FACTOR XII (HAGEMAN), OF FACTOR X (STUART) AND OF FIBRINOGEN IN LIVER PATIENTS].
    BOLANDRINA E; SOARDI F
    Gazz Int Med Chir; 1964 Jan; 68():63-79. PubMed ID: 14123792
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4.
    Dumenco LL; Everson B; Culp LA; Ratnoff OD
    J Lab Clin Med; 1988 Sep; 112(3):394-400. PubMed ID: 3045234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.